ArticleBreast cancer research and treatment2025
Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
purposeMale breast cancer (mBC) is rare and accounts for ~ 1% of all breast cancer cases in the United States (US), and mBC incidence has risen in recent years. This study sought to examine mBC mortality disparities across racial/ethnic groups and associated socioeconomic determinants at the national level.
methodsThis retrospective study analyzed the 2010-2021 National Cancer Database. Patients were eligible if they were ≥ 18 years, were male sex, and had stage I-IV disease, with available data on receptor status. Overall survival (OS) was modeled using Cox regression adjusting for demographic, socioeconomic, and clinicopathologic factors.
resultsOf 20,470 mBC (mean age, 66.2 [SD, 12.6] years), 2.5% were Asian or Pacific Islander, 13.8% Black, 4.0% Hispanic, and 78.2% White. After controlling for clinicopathologic characteristics, Black patients had worse OS than White patients (adjusted hazard ratio [AHR], 1.22; 95% CI, 1.12-1.32); however, when further adjusting for socioeconomic factors, this difference was no longer significant (AHR, 1.09; 95% CI, 0.99-1.21). Hispanic patients (AHR, 0.76; 95% CI, 0.62-0.94) had a lower mortality risk. OS varied across tumor stages and molecular subtypes. In the triple-negative mBC cohort, Asian or Pacific Islander patients had worse OS than White patients (AHR, 2.35; 95% CI, 1.21-4.55), warranting further investigation. Additionally, lower median household income, lack of health insurance, Medicaid/Medicare, and comorbidities were associated with a higher mortality risk.
conclusionOur findings highlight elevated mortality risks of mBC among Black patients, among Asian or Pacific Islander patients with TNBC, and associations with household income and insurance status. Interventions addressing socioeconomic inequities that impact access to cancer care programs and services may help reduce racial/ethnic disparities and improve mBC survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.